GMAB vs. ICLR: Genmab vs. ICON Stock Comparison

Company Profile

Genmab (GMAB) and ICON (ICLR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GMAB is classified in Biotechnology while ICLR is classified in Life Sciences Tools & Services.

ICON (ICLR) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Genmab (GMAB) at 12.07% sits in the top ROE quartile, while ICON (ICLR) at 4.70% is closer to the peer norm — stronger capital efficiency for GMAB.

For every dollar of sales, both Genmab (GMAB) at 16.97% and ICON (ICLR) at 5.26% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Genmab (GMAB) at 37.15% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Genmab (GMAB) at 19.19% and ICON (ICLR) at 0.76% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Genmab (GMAB) at -9.23% is around its peer norm for EPS growth, while ICON (ICLR) at -71.56% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

Both Genmab (GMAB) at 2.45 and ICON (ICLR) at 1.32 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ICON (ICLR) at 0.38 carries an industry-typical debt-to-equity mix, while Genmab (GMAB) at 0.82 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Genmab (GMAB) nor ICON (ICLR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Genmab (GMAB) nor ICON (ICLR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both Genmab (GMAB) at 45.84 and ICON (ICLR) at 81.90 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Genmab (GMAB) at 7.68 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile against book while Genmab (GMAB) at 5.36 is valued near its industry’s middle — ICLR is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics